Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
OTCMKTS
· Delayed Price · Currency is USD
1.970
+0.730 (58.87%)
At close: Dec 31, 2024
SHJBF Revenue
Shanghai Junshi Biosciences had revenue of 500.59M CNY in the quarter ending March 31, 2025, with 31.46% growth. This brings the company's revenue in the last twelve months to 2.07B, up 27.02% year-over-year. In the year 2024, Shanghai Junshi Biosciences had annual revenue of 1.95B with 29.67% growth.
Revenue (ttm)
2.07B CNY
Revenue Growth
+27.02%
P/S Ratio
14.46
Revenue / Employee
802.21K CNY
Employees
2,578
Market Cap
4.12B USD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.95B | 445.77M | 29.67% |
Dec 31, 2023 | 1.50B | 49.06M | 3.38% |
Dec 31, 2022 | 1.45B | -2.57B | -63.89% |
Dec 31, 2021 | 4.02B | 2.43B | 152.36% |
Dec 31, 2020 | 1.59B | 819.81M | 105.77% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |